A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients

por Tate, Sonya C., Sykes, Amanda K., Kulanthaivel, Palaniappan, Chan, Edward M., Turner, P. Kellie, Cronier, Damien M.
Publicado en Clin Pharmacokinet (2017)

SUMO Pathway Dependent Recruitment of Cellular Repressors to Herpes Simplex Virus Type 1 Genomes

por Cuchet-Lourenço, Delphine, Boutell, Chris, Lukashchuk, Vera, Grant, Kyle, Sykes, Amanda, Murray, Jill, Orr, Anne, Everett, Roger D.
Publicado 2011

PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication

por Cuchet, Delphine, Sykes, Amanda, Nicolas, Armel, Orr, Anne, Murray, Jill, Sirma, Hüseyin, Heeren, Joerg, Bartelt, Alexander, Everett, Roger D.
Publicado 2011

Development and Application of a Mechanistic Population Modeling Approach to Describe Abemaciclib Pharmacokinetics

por Chigutsa, Emmanuel, Kambhampati, Siva Rama Prasad, Karen Sykes, Amanda, Posada, Maria M., van der Walt, Jan‐Stefan, Turner, P. Kellie
Publicado en CPT Pharmacometrics Syst Pharmacol (2020)

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers

por Zhang, Jian, Yang, Nong, Ji, Dongmei, Shen, Weina, Li, Wenhua, Han, Rubing, Wang, Ning, Tao, Haoxun, Chapman, Sonya C., Sykes, Amanda K., Zhang, Wanli, Hu, Xichun
Publicado en Target Oncol (2021)

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

por Simon, George R., Ilaria, Robert L., Sovak, Mika A., Williams, Charles C., Haura, Eric B., Cleverly, Ann L., Sykes, Amanda K., Wagner, Margaret M., de Alwis, Dinesh P., Slapak, Christopher A., Miller, Mary A., Spriggs, David R.
Publicado 2011